Małgorzata M Miller1, Jessica Lowe2, Muhib Khan2, Muhammad U Azeem3, Susanne Muehlschlegel3,4,5, Adalia H Jun-O'Connell3, Richard P Goddeau3, Majaz Moonis3, Danielle Gritters6, Brian Silver3, Nils Henninger3,7. 1. Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA. malgorzata.miller@umassmemorial.org. 2. Division of Neurology, Neuroscience Institute, Spectrum Health, Grand Rapids, MI, USA. 3. Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA. 4. Department of Surgery, University of Massachusetts Medical School, Worcester, MA, USA. 5. Department of Anesthesia and Critical Care, University of Massachusetts Medical School, Worcester, MA, USA. 6. Spectrum Health Office of Research, Spectrum Health, Grand Rapids, MI, USA. 7. Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA, USA.
Abstract
BACKGROUND/ OBJECTIVE: Recent studies indicated that functional outcome after intracranial hemorrhage (ICH) related to direct oral anticoagulation (DOAC-ICH) is similar, if not better, than vitamin K antagonist (VKA)-related ICH (VKA-ICH) due to a smaller initial hematoma volume (HV). However, the association with hematoma expansion (HE) and location is not well understood. METHODS: We retrospectively analyzed 102 consecutive patients with acute non-traumatic ICH on oral anticoagulation therapy to determine HV and HE stratified by hematoma location, and the relation to the 90-day outcome. RESULTS: DOAC-ICH (n = 25) and VKA-ICH (n = 77) had a similar admission HV and HE (unadjusted p > 0.05, each). Targeted reversal strategies were used in 93.5% of VKA-ICH versus 8% of DOAC-ICH. After adjustment, an unfavorable 90-day functional outcome (modified Rankin scale score 4-6) was independently associated with a lower admission Glasgow Coma Scale score (OR 1.63; 95% CI 1.26-2.10; p < 0.001) and greater HV (OR 1.03; 95% confidence interval (CI) 1.00-1.05; p = 0.046). After exclusion of patients without follow-up head computed tomography to allow for adjustment by occurrence of HE, VKA-ICH was associated with an approximately 3.5 times greater odds for a poor 90-day outcome (OR 3.64; 95% CI 1.01-13.09; p = 0.048). However, there was no significant association of the oral anticoagulant strategy with 90-day outcome in the entire cohort (OR 2.85; 95% CI 0.69-11.86; p = 0.15). CONCLUSIONS: DOAC use did not relate to worse HE, HV, and functional outcome after ICH, adding to the notion that DOAC is a safe alternative to VKA even in the absence of access to targeted reversal strategies (which are still not universally available).
BACKGROUND/ OBJECTIVE: Recent studies indicated that functional outcome after intracranial hemorrhage (ICH) related to direct oral anticoagulation (DOAC-ICH) is similar, if not better, than vitamin K antagonist (VKA)-related ICH (VKA-ICH) due to a smaller initial hematoma volume (HV). However, the association with hematoma expansion (HE) and location is not well understood. METHODS: We retrospectively analyzed 102 consecutive patients with acute non-traumatic ICH on oral anticoagulation therapy to determine HV and HE stratified by hematoma location, and the relation to the 90-day outcome. RESULTS: DOAC-ICH (n = 25) and VKA-ICH (n = 77) had a similar admission HV and HE (unadjusted p > 0.05, each). Targeted reversal strategies were used in 93.5% of VKA-ICH versus 8% of DOAC-ICH. After adjustment, an unfavorable 90-day functional outcome (modified Rankin scale score 4-6) was independently associated with a lower admission Glasgow Coma Scale score (OR 1.63; 95% CI 1.26-2.10; p < 0.001) and greater HV (OR 1.03; 95% confidence interval (CI) 1.00-1.05; p = 0.046). After exclusion of patients without follow-up head computed tomography to allow for adjustment by occurrence of HE, VKA-ICH was associated with an approximately 3.5 times greater odds for a poor 90-day outcome (OR 3.64; 95% CI 1.01-13.09; p = 0.048). However, there was no significant association of the oral anticoagulant strategy with 90-day outcome in the entire cohort (OR 2.85; 95% CI 0.69-11.86; p = 0.15). CONCLUSIONS: DOAC use did not relate to worse HE, HV, and functional outcome after ICH, adding to the notion that DOAC is a safe alternative to VKA even in the absence of access to targeted reversal strategies (which are still not universally available).
Entities:
Keywords:
Direct oral anticoagulants; Intracranial hemorrhage; Warfarin
Authors: Paulus Kirchhof; Stefano Benussi; Dipak Kotecha; Anders Ahlsson; Dan Atar; Barbara Casadei; Manuel Castella; Hans-Christoph Diener; Hein Heidbuchel; Jeroen Hendriks; Gerhard Hindricks; Antonis S Manolis; Jonas Oldgren; Bogdan Alexandru Popescu; Ulrich Schotten; Bart Van Putte; Panagiotis Vardas; Stefan Agewall; John Camm; Gonzalo Baron Esquivias; Werner Budts; Scipione Carerj; Filip Casselman; Antonio Coca; Raffaele De Caterina; Spiridon Deftereos; Dobromir Dobrev; José M Ferro; Gerasimos Filippatos; Donna Fitzsimons; Bulent Gorenek; Maxine Guenoun; Stefan H Hohnloser; Philippe Kolh; Gregory Y H Lip; Athanasios Manolis; John McMurray; Piotr Ponikowski; Raphael Rosenhek; Frank Ruschitzka; Irina Savelieva; Sanjay Sharma; Piotr Suwalski; Juan Luis Tamargo; Clare J Taylor; Isabelle C Van Gelder; Adriaan A Voors; Stephan Windecker; Jose Luis Zamorano; Katja Zeppenfeld Journal: Europace Date: 2016-08-27 Impact factor: 5.214
Authors: Gregoire Boulouis; Andrea Morotti; Marco Pasi; Joshua N Goldstein; M Edip Gurol; Andreas Charidimou Journal: J Neurol Neurosurg Psychiatry Date: 2017-10-13 Impact factor: 10.154
Authors: Christian T Ruff; Robert P Giugliano; Eugene Braunwald; Elaine B Hoffman; Naveen Deenadayalu; Michael D Ezekowitz; A John Camm; Jeffrey I Weitz; Basil S Lewis; Alexander Parkhomenko; Takeshi Yamashita; Elliott M Antman Journal: Lancet Date: 2013-12-04 Impact factor: 79.321
Authors: Cláudia Marques-Matos; José Nuno Alves; João Pedro Marto; Joana Afonso Ribeiro; Ana Monteiro; José Araújo; Fernando Silva; Fátima Grenho; Miguel Viana-Baptista; João Sargento-Freitas; João Pinho; Elsa Azevedo Journal: Int J Stroke Date: 2016-12-01 Impact factor: 5.266
Authors: M L Flaherty; H Tao; M Haverbusch; P Sekar; D Kleindorfer; B Kissela; P Khatri; B Stettler; O Adeoye; C J Moomaw; J P Broderick; D Woo Journal: Neurology Date: 2008-09-30 Impact factor: 9.910
Authors: Duncan Wilson; Andreas Charidimou; Clare Shakeshaft; Gareth Ambler; Mark White; Hannah Cohen; Tarek Yousry; Rustam Al-Shahi Salman; Gregory Y H Lip; Martin M Brown; Hans Rolf Jäger; David J Werring Journal: Neurology Date: 2015-12-30 Impact factor: 9.910
Authors: Duncan Wilson; David J Seiffge; Christopher Traenka; Ghazala Basir; Jan C Purrucker; Timolaos Rizos; Oluwaseun A Sobowale; Hanne Sallinen; Shin-Joe Yeh; Teddy Y Wu; Marc Ferrigno; Rik Houben; Floris H B M Schreuder; Luke A Perry; Jun Tanaka; Marion Boulanger; Rustam Al-Shahi Salman; Hans R Jäger; Gareth Ambler; Clare Shakeshaft; Yusuke Yakushiji; Philip M C Choi; Julie Staals; Charlotte Cordonnier; Jiann-Shing Jeng; Roland Veltkamp; Dar Dowlatshahi; Stefan T Engelter; Adrian R Parry-Jones; Atte Meretoja; David J Werring Journal: Neurology Date: 2017-04-05 Impact factor: 9.910